An easily accessible diagnostic test called pain-related evoked potentials with concentric electrodes (PrEP-CE) may help detect the onset of hereditary transthyretin amyloidosis with polyneuropathy…
Featured Articles
Signs of more advanced heart disease and the presence of nerve involvement are associated with a higher risk of worse outcomes, including heart failure, hospitalization due to heart disease, and death, in people with hereditary transthyretin amyloid cardiomyopathy (hATTR-CM). That’s according to a nationwide study in Spain, which also…
Attruby (acoramidis) slows disease progression and significantly reduces death and cardiovascular-related hospitalizations in adults with hereditary or wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) across…
Overactivation of Rac1, a protein that regulates components of a cell’s skeleton, may drive early nerve damage in hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN),…
Blood levels of signaling molecules that promote tissue scarring, or fibrosis, are elevated in people with transthyretin amyloid cardiomyopathy (ATTR-CM), and higher levels of…
Discussion
As an advocate for the New Zealand Amyloidosis Patients Association since 2019, I am acutely aware that when there is no center of excellence or coordinated…
Perspectives
-
Discussion
-
Discussion
-
Discussion
-
Discussion
-
Discussion
-
Discussion
Newly diagnosed? Start your journey here.
Need to know
Becoming educated and informed about FAP is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
Personal experiences
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your FAP journey.
Treatment
There is no cure for FAP yet, but there are treatments that can help manage the disease. Learn more about the approved and experimental therapies here.